Why CBD in addiction therapy?

by Duncan Fisher

September 21, 2022 - 2 min read

Abused drugs promote short- and long-term changes in how the endocannabinoid system, part of the body’s onboard cell-signaling network, regulates dopamine function in limbic functions. They commandeer neural systems related to the reward sensation in recreational drug use. The cannabinoid molecules in marijuana have preferential access to the CB1 neural receptor in particular, and should therefore modulate endocannabinoid-dependent processing of reward stimuli. In this lies the rationale for considering cannabinoid-based treatments for drug addiction, probably quite widely. 

Animal stud­ies have indeed shown the possible effects of cannabidiol (CBD) on opioid and psychostimulant addiction. Human studies as well have yielded data supporting use of CBD in cannabis and tobacco dependence. SLV330, an experimental CB1 receptor antagonist, has also been shown to attenuate ethanol and nicotine seeking in rats. 

In precision studies, neutral CB1 antagonists appear more effective than orthosteric or inverse agonists, or negative allosteric modulators. 

The inverse agonist SR14176 (rimonabant) has significantly inhibited cocaine, heroin, and nicotine self-administration in rats, though, unexpectedly, SR14176 by itself produces dysphoria. The neutral antagonists AM4113 and PIMSR1, administered together, have significantly attenuated cocaine, nicotine, and heroin self-administration in another rat model, though by themselves they did not have the same effect. The negative allosteric modulators GAT358 and GAT 369 had no effect when measured against nicotine-enhanced neural activity.

There is much to learn about the wider mechanisms of action in these agents and in addiction overall. In addiction to nicotine and cocaine, and possibly alcohol, there are epigenetic mechanisms at work, that include DNA methylation, histone modification, and alterations in microRNAs. It is known at least that the endocannabinoid system is pivotal in each of these. 

 

DiolPure products contain PureForm CBD™ transformed from aromatic terpenes for pharmaceutical-grade purity. PureForm CBD™ is bioidentical to CBD extracted from hemp and cannabis, but free of any residual cannabinoids like THC or impurities or chemicals that can associate with traditional plant-derived production processes. 


The foregoing is a report on trends and developments in cannabinoid industry research. No product description herein is intended as a recommendation for diagnosis, treatment, cure or prevention of any disease or syndrome. 

 





Cannabigerol (CBG): Another promising cannabinoid?

Cannabigerol (CBG): Another promising cannabinoid?

For some good reasons, research and commercial attention is beginning to turn to cannabigerol, or 'CBG'. 
Read More

October 04, 2022 2 min read

Up close: Cannabinoids in Huntington's chorea

Up close: Cannabinoids in Huntington's chorea

In vitro and in vivo models of Huntington's disease, an inherited condition in which nerve cells in the brain break down over time, show disease-related alterations in the endocannabinoid system, part of the body’s neural cell-signaling network, and the dopamine regulatory system downstream. 
Read More

October 03, 2022 3 min read

Up close: Cannabinoids in neurodegenerative diseases

Up close: Cannabinoids in neurodegenerative diseases

Modulation of cannabinoid receptor signaling should represent a viable therapeutic target in neurodegenerative diseases. 
Read More

September 30, 2022 2 min read

Follow us on Instagram

Net Orders Checkout

Item Price Qty Total
Subtotal $ 0.00
Shipping
Total

Shipping Address

Shipping Methods